Over the last decade, value-based reimbursement models have garnered a mountain of interest, but challenges in building a data infrastructure that can identify outcome metrics and logistics to dispense payments have largely relegated these models to anecdotal status. Recent deals by Pfizer and Takeda may indicate a step forward. Precision’s Ryan Cox weighs in on the evolving state of value based reimbursement models.
Read the full article here!
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
